Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Total Non-Current Liabilities: 2019-2024

Historic Total Non-Current Liabilities for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $105.1 million.

  • Pharming Group N.V's Total Non-Current Liabilities rose 1.12% to $121.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.2 million, marking a year-over-year increase of 1.12%. This contributed to the annual value of $105.1 million for FY2024, which is 36.71% down from last year.
  • Pharming Group N.V's Total Non-Current Liabilities amounted to $105.1 million in FY2024, which was down 36.71% from $166.1 million recorded in FY2023.
  • In the past 5 years, Pharming Group N.V's Total Non-Current Liabilities registered a high of $166.1 million during FY2023, and its lowest value of $105.1 million during FY2024.
  • Over the past 3 years, Pharming Group N.V's median Total Non-Current Liabilities value was $161.5 million (recorded in 2022), while the average stood at $144.2 million.
  • In the last 5 years, Pharming Group N.V's Total Non-Current Liabilities spiked by 551.63% in 2020 and then tumbled by 36.71% in 2024.
  • Yearly analysis of 5 years shows Pharming Group N.V's Total Non-Current Liabilities stood at $158.2 million in 2020, then dropped by 0.34% to $157.6 million in 2021, then grew by 2.43% to $161.5 million in 2022, then increased by 2.88% to $166.1 million in 2023, then plummeted by 36.71% to $105.1 million in 2024.